Epithelial-Mesenchymal Transition and Drug Resistance: Role, Molecular Mechanisms, and Therapeutic Strategies
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
SummaryChemotherapy is an important therapeutic option for most cancer patients; however, one major obstacle is the occurrence of drug resistance which usually leads to failure of the chemotherapy. Emerging evidence suggests that there are intricate links between epithelial-mesenchymal transition (EMT)-type cells and drug resistance in tumors. The process of drug resistance can be regulated by a diverse array of cytokines and growth factors, higher apoptotic threshold, aerobic glycolysis, regions of hypoxia, and elevated activity of drug efflux transporters. Moreover, recent reports have indicated that the emergence of drug resistance may occur as a result of EMT. In this regard, most drug-resistant cancers contain a subpopulation of cells with stem-like and mesenchymal features that are resistant to chemotherapy. In this review, we will explain potential mechanisms for the association between EMT induction and the emergence of drug resistance, and discuss new approaches and drugs for the clinical management of drug-resistant cancer induced by EMT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Acharya, A., Baek, S. T., Huang, G., Eskiocak, B., Goetsch, S., Sung, C. Y., Banfi, S., Sauer, M. F., Olsen, G. S., Duffield, J. S., et al. (2012) · Development · doi:10.1242/dev.079970 · Cited by 498
Role of integrated cancer nanomedicine in overcoming drug resistance
Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.012 · Cited by 343
Cufí, S., Vazquez-Martin, A., Oliveras-Ferraros, C., Martin-Castillo, B., Joven, J., & Menendez, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.22.14048 · Cited by 216
Lisanti, M. P., Martinez-Outschoorn, U. E., Chiavarina, B., Pavlides, S., Whitaker-Menezes, D., Tsirigos, A., Witkiewicz, A. K., Lin, Z., Balliet, R. M., Howell, A., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.6.13370 · Cited by 199
Cited by
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Du, B., & Shim, J. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 807
New horizons in tumor microenvironment biology: challenges and opportunities
Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., Hu, G., & Sun, Y. (2015) · BMC Medicine · doi:10.1186/s12916-015-0278-7 · Cited by 704
“In this regard, most treatment-resistant cancers harbor a subgroup of cells with stem-like or mesenchymal features that are resistant to cancer therapies [52].”
BackgroundZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
Zhang, P., Sun, Y., & Ma, L. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1006048 · Cited by 611
“therapy resistance in cancer, including radioresistance, chemoresistance, HER2, EGFR, endocrine and other targeted therapy resistance.(11,12,44,60-64) A provocative study by Weinberg and colleagues demonstrated that basal, but not luminal breast cancer cells can readily convert from noncancer stem cell state to cancer…”
BackgroundErin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance
Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H. (2020) · Cells · doi:10.3390/cells9020428 · Cited by 213
“These fibroblasts allow tumor cells to undergo EMT through the secretion of cytokines, such as interleukin-6 an t e ai i cer, - 1 [20,24,38,91,92].”
BackgroundImproving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer
Kroon, J., Kooijman, S., Cho, N.-J., Storm, G., & van der Pluijm, G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.03.003 · Cited by 64
Nestin-Expressing Cells in the Lung: The Bad and the Good Parts
Jaramillo-Rangel, G., Chávez-Briones, M.-D.-L., Ancer-Arellano, A., & Ortega-Martínez, M. (2021) · Cells · doi:10.3390/cells10123413 · Cited by 25
Metadata
- Authors
- Sui, H., Zhu, L., Deng, W., & Li, Q.
- Venue
- Oncology Research and Treatment
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 37
- Issue
- 10
- Pages
- 584-589
- ISSN
- 2296-5262 (ISSN-L)
- 2296-5270
- OpenAlex
- W2058468989
- Cited by
- 86
- References
- 8
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.